A study testing Pucotenlimab with chemo before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial is for people with advanced head and neck cancer that has not been treated yet. It tests a combination of an immunotherapy drug (Pucotenlimab) and chemotherapy given before surgery to see if it can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with a type of head and neck cancer (squamous cell) in the mouth, throat, or voice box that has spread to nearby areas but not far away
- Able to have surgery to remove the cancer, followed by standard radiation or chemo-radiation
- 18 to 70 years old
- Good overall health (able to do daily activities without help)
- Never had treatment for this cancer before
- Willing to provide a tumor tissue sample for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
This trial tests whether a combination of two drugs (Becotatug Vedotin and Putlimab) before surgery and then radiation after surgery can help people with locally advanced head and neck squamous cell carcinoma. It aims to see if this approach is safe and effective.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests a combination of three drugs (MRG003, pucotenlimab, and possibly cisplatin) given before surgery for people with a specific type of head and neck cancer that is EGFR-positive and has not been treated yet. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.